See our newest life science pick: Thiogenesis Therapeutics, Corp. (TSXV: TTI)(OTCQX: TTIPF).
Major Top Reasons to Invest in Thiogenesis:
- Same Proven Molecule, Dramatically Better Delivery: The FDA has already approved the active ingredient (cysteamine) twice for cystinosis—first as immediate-release Cystagon (4x/day) and later as delayed-release Procysbi (2x/day). Thiogenesis is offering a major improvement on the delivery of that proven molecule with TTI-0102.
- Patented Prodrug with Sustained Absorption: TTI-0102 is a patented cysteamine prodrug that provides sustained absorption, enabling once-daily bedtime dosing with significantly reduced side effects.
- Critical Unmet Need in a Devastating Orphan Disease: Cystinosis is a rare, life-long genetic disease that leads to kidney failure without therapy. Cysteamine is the only approved disease-modifying treatment. Because it is genetic, patients start therapy as infants and face lifelong adherence challenges.
- Powder Formulation Solves the Pill Burden: Current standard of care requires swallowing massive pill volumes—ranging from a dozen capsules daily for young children to 20–30 daily capsules for adults. TTI-0102 is delivered in an easy once-daily powder format, eliminating pill fatigue entirely.
- Overcoming Severe Social and Gastrointestinal Side Effects: Cysteamine causes immediate nausea and a pungent sulfur (rotten egg) body odor and breath. Taking it twice daily forces patients to live with constant daytime odor, leading older kids and young adults to skip daytime doses and jeopardize their kidneys. Once-daily bedtime dosing with TTI-0102 allows patients to sleep through the peak metabolic phase, radically improving compliance.
- The Exact Leadership Team That Did It Before: The Chairman, CEO, and two board members led Raptor Pharmaceuticals, where they successfully developed 2x/day Procysbi through clinical trials, gained FDA approval, and sold Raptor to Horizon for $800M. They know the molecule, the clinical pathway, the regulators, and commercialization better than anyone.
- Backed by Institutional Biotech Specialists: Dedicated healthcare fund Rosalind Advisors participated in the company’s financing after conducting extensive diligence with top-tier biotech researchers, and they now hold a board seat.
- Large, High-Value Proven Market: Procysbi generates over $233M in annual US sales ($350M globally). With a superior once-daily powder profile, TTI-0102 is positioned to capture substantial market share without requiring aggressive pricing.
- Fast, Cost-Effective Clinical Catalyst: Thiogenesis is advancing an Investigator-Initiated Study (IIS) for TTI-0102 in cystinosis patients in the coming months with leading global experts at Emory University. This study delivers important human confirmatory data rapidly and cost-effectively, serving as key supporting data for upcoming FDA Phase 3 discussions.
- Significant Institutional Runway: Delivery of positive clinical data is expected to drive strong institutional interest in the US. Backed by the pedigree of a management team that has already delivered an $800M exit in this exact indication, Thiogenesis is already attracting early interest from US investment bankers and analysts.
To summarize: an FDA-approved molecule with a vastly superior once-daily delivery mechanism, an executive team that built and sold the current standard of care for $800M, validation from a specialized biotech fund, an established $350M global market, and near-term human data that paves the way for a streamlined Phase 3 and US institutional expansion.
We will be introducing management to you over the coming months. Stay tuned!!!!
Website: https://www.thiogenesis.com/
Corporate Presentation: PowerPoint Presentation
LinkedIn: https://www.linkedin.com/company/thiogenesis-therapeutics-corp/
